Compare HCA Health Inc (HCA) vs Unilever plc (UL) Price & Performance

HCA Healthcare trades at $370.74, down 0.12% on the day, with a bearish technical signal but strong fundamentals including consistent earnings beats and revenue growth to $75.6 billion in 2025. The stock faces headwinds from lowered 2026 guidance and negative news flow, but maintains a solid valuation with a P/E of 12.79 and positive analyst consensus.

The outlook is mixed: attractive valuation and operational strength support upside to the $469.40 price target, but near-term risks from payer mix shifts and legal investigations warrant caution. Long-term growth drivers include capacity expansion and medical advancements, though investor sentiment is currently pressured.

Unilever (UL) trades at $62.18, down 0.34% today, with a bullish technical signal from moving averages and neutral oscillators. Recent quarterly earnings missed expectations, but the company maintains strong profitability with a 46.95% gross margin and 18.75% net margin. Key developments include a pending food business divestiture to McCormick and a $270 million innovation center investment, signaling strategic focus on core brands and digital transformation.

The outlook is mixed: valuation appears fair with a P/E of 21.15, but earnings misses and competitive pressures pose risks. Analyst consensus is cautious with 51% hold ratings. Long-term opportunities lie in emerging market growth and cost efficiencies, though near-term execution and macroeconomic headwinds require monitoring.